查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
急性肾损伤 (AKI) 治疗市场 – 2023 年至 2028 年预测
市场调查报告书
商品编码
1295377

急性肾损伤 (AKI) 治疗市场 – 2023 年至 2028 年预测

Acute Kidney Injury (AKI) Disease Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

急性肾损伤 (AKI) 治疗市场预计复合年增长率为 2.63%，从 2021 年的 310.7 亿美元增至 2028 年的 372.53 亿美元。

全球急性肾损伤治疗市场受到急性肾损伤发病率上升的显着影响。 美国国家肾臟基金会估计，美国大约有 3700 万人患有肾臟疾病。 由于衰老、不良饮食习惯和大量饮酒，肾臟受损的风险正在增加。 对乙□氨基酚和其他药物过量、肝炎、自身免疫性疾病和代谢性疾病也是导致市场爆炸的因素。 此外，不断上涨的医疗保健成本和政府改善医疗保健系统的措施预计将增加市场收入。 然而，透析服务的高成本和患者对长期治疗计划的依从性低正在阻碍市场扩张。

与生活方式相关的疾病迅速增加

急性肾损伤是肾功能突然暂时丧失。 这种情况可能是由于糖尿病或高血压等一些潜在疾病引起的。 由于人们生活方式的改变，许多疾病不断出现。 典型的例子包括糖尿病、肥胖症、高血压以及与肝臟和肾臟有关的疾病。 世界卫生组织 (WHO) 估计，影响一个人的健康和生活质量的变量中有 60% 与其生活方式有关。 人们的健康受到加工食品、垃圾食品和不良饮食习惯的影响。 此外，缺乏锻炼或缺乏身体活动会增加消化不良和随后的急性肾损伤的风险。 人们越来越沉迷于毒品、酒精和吸烟，所有这些都会对健康产生负面影响。 缺乏身体活动和缺乏锻炼也会增加消化不良和相关急性肾损伤的可能性。 人们沉迷于酒精、吸烟和毒品，这也对健康产生负面影响。 例如，国际肾脏病学会估计全球每年发生超过 1330 万例急性肾损伤病例。 此外，全世界每年有 170 万人死于急性肾损伤。 在美国，大约 1% 的住院患者患有 AKI。

此外，政府加速医□□疗保健创新的举措也正在加速市场扩□□张。

根据国家科学基金会和白宫科学技术政策办公室的公告，国家人工智能研究资源工作组于 2021 年 6 月成立。 该工作组将製定扩大教育资源和基本工具的路线图，以促进全国范围内的人工智能创新。 此外，行业领先公司正专注于开发急性肾损伤治疗药物，预计这将在预测期内推动全球急性肾损伤治疗市场的增长。

按 RRT 类型，急性肾损伤治疗市场分为持续性 RRT 和间歇性 RRT。

与间歇性 RRT 不同，连续透析以缓慢、恆定的速度从血液中去除水分和废物，从而降低了血流动力学不稳定的患者无法耐受这种去除的风险。 儘管这种类型的 RRT 更适合治疗 AKI，但在许多经济体中，高成本仍然是采用 CRRT 的主要障碍，因为这些经济体的目标是负担得起昂贵的医疗程序。

CRRT 在 AKI 治疗市场的增长也得到了医疗培训计划和教育计划的支持。 肾脏病专家、重症监护医师和重症监护护士等医疗保健专业人员接受了有关实施 CRRT 的原则和实践方面的培训和教育。 训练有素的医务人员为 CRRT 在临床实践中的广泛采用和成功做出了贡献。

北美和欧洲将在 2021 年占据很大的市场份额。

按地区划分，全球 AKI 疾病治疗市场分为北美、南美、欧洲、中东和非洲以及亚太地区。 由于中国和印度等国家慢性病病例的增加，以及该地区医疗旅游业的蓬勃发展，亚太地区在预测期内将出现强劲的复合年增长率。看来会的。

在北美，美国糖尿病的高患病率正在增加急性肾损伤患者的数量。 据美国疾病控制与预防中心 (CDC) 称，AKI 是美国的一个重大公共卫生问题，每年影响超过 50 万人，并导致超过 10 万人死亡。 AKI 还与医疗费用增加有关，美国每年 AKI 住院费用估计为 100 亿美元。

此外，肾臟替代疗法 (RRT)（包括血液透析和腹膜透析）等创新疗法的采用正在增加。 这些治疗方法变得越来越广泛且负担得起，使更多患者能够获得所需的护理。

市场趋势：

  • 2021 年9 月，Sentien Biotechnologies, Inc.（一家开发新型细胞疗法的临床阶段技术进步公司）被宣布成为生物医学科学部的成员，生物医学科学部是美国负责准备和响应的助理部长的下属部门。卫生与公众服务部：我们与高级研究与发展局 (BARDA) 合作，宣布将在急性肾损伤患者中测试 Sentien 的体外细胞疗法 SBI-101。
  • 医疗器械、服务和解决方案领域的全球领导者美敦力公司 (Medtronic plc) 于 2020 年 12 月宣布在美国正式推出 Carpe Diem 心臟肾小儿透析急救设备。 Carpe Diem 系统是同类产品中第一个被推荐用于因急性肾损伤或液体超负荷而需要血液透析或血液滤过治疗的患者的系统。 专为体重 2.5-10 公斤的患者进行长期肾臟替代治疗而设计。

内容

第 1 章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第 2 章研究方法

  • 调查数据
  • 调查过程

第 3 章执行摘要

  • 研究亮点

第 4 章市场动态

  • 市场促进因素
  • 市场抑制因素
  • 波特五力分析
  • 行业价值链分析

第 5 章急性肾损伤治疗市场：按组成部分

  • 简介
  • 治疗
    • 药物类型
    • 透析
  • 诊断
    • 尿液分析
    • 验血
    • 肾小球滤过率 (GFR)
    • 图像检查
    • 肾活检

第 6 章急性肾损伤治疗市场：按 RRT 类型划分

  • 简介
  • 持久
  • 间歇性

第 7 章急性肾损伤治疗市场：按地区

  • 简介
  • 北美
    • 按组件
    • 按 RRT 类型
    • 按国家/地区
  • 南美洲
    • 按组件
    • 按 RRT 类型
    • 按国家/地区
  • 欧洲
    • 按组件
    • 按 RRT 类型
    • 按国家/地区
  • 中东和非洲
    • 按组件
    • 按 RRT 类型
    • 按国家/地区
  • 亚太地区
    • 按组件
    • 按 RRT 类型
    • 按国家/地区

第 8 章竞争格局与分析

  • 主要公司及战略分析
  • 新兴公司和市场盈利能力
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第 9 章公司简介

  • Exponential Biotherapies, Inc.
  • Nikkiso America, Inc.
  • Am-Pharma
  • Renalguard Solutions, Inc.
  • Angion Biomedica Corp.
  • Thrasos Therapeutics Inc.
  • Atoxbio
  • Sentien Biotechnologies, Inc
简介目录
Product Code: KSI061612284

The Acute Kidney Injury (AKI) disease treatment market is predicted to grow at a CAGR of 2.63% from US$31.070 billion in 2021 to US$37.253 billion by 2028.

The global market for acute kidney injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased because of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

The surge in lifestyle diseases.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organization estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage. People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Further, government efforts to speed up healthcare innovation are also accelerating market expansion.

The National Artificial Intelligence Research Resource Task Force was established in June 2021 as a result of an announcement made by the National Science Foundation and the White House Office of Science and Technology Policy. This task force will develop a roadmap for the expansion of educational resources and essential tools that will promote Al innovation across the country. Moreover, the industry's leading players are concentrating on the development of acute renal injury therapies, which is anticipated to propel the growth of the worldwide acute kidney injury treatment market during the forecast period.

By type of RRT, the AKI disease treatment market has been segmented into continuous and intermittent.

Unlike intermittent RRT, continuous dialysis involves the removal of water and waste from the blood takes place at a slow and steady rate which reduces the risk of this removal being poorly tolerated by patients who are hemodynamically unstable. Although this type of RRT is better suited for the treatment of AKI, their higher cost continues to be a major factor hindering their adoption across many economies where the affordability of expensive medical procedures is still a goal.

The growth of CRRT in the AKI treatment market is also supported by medical training programs and educational initiatives. Healthcare professionals, including nephrologists, intensivists, and critical care nurses, receive training and education on the principles and practical aspects of performing CRRT. Well-trained medical staff contributes to the wider adoption and successful implementation of CRRT in clinical settings.

North America and Europe held a significant market share of the market in 2021.

By geography, the global AKI disease treatment market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. APAC will witness a significant CAGR during the forecast period owing to the rising cases of chronic diseases in countries like China and India, along with the booming medical tourism industry across the region.

In North America, the high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US.

Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Market Developments:

  • In September 2021, Sentien Biotechnologies, Inc., a clinical-stage technological advancement company developing novel cell therapy methods, announced a collaboration with the biomedical field Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services Assistant Secretary for Preparedness and Response, to test Sentien's ex vivo cell therapy, SBI-101, in patients with acute kidney injuries.
  • The official introduction of the Carpediem cardio-renal pediatric dialysis emergency machine in the United States was announced by Medtronic plc, a world leader in medical equipment, services, and solutions, in December 2020. The first of its type Carpediem system is recommended for use in patients needing hemodialysis or hemofiltration therapy due to acute renal damage or fluid overload. It is designed to give patients who weigh between 2.5 and 10 kilograms continuous renal replacement treatment.

Market Segmentation:

By Component

  • Treatment
  • Drug Type
  • Isotonic Solution
  • Antibiotic
  • Others
  • Dialysis
  • Diagnosis
  • Urine Tests
  • Blood Tests
  • Glomerular Filtration Rate (GFR)
  • Imaging tests
  • Kidney Biopsy

By Type of RRT

  • Continuous
  • Intermittent

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY COMPONENT

  • 5.1. Introduction
  • 5.2. Treatment
    • 5.2.1. Drug Type
    • 5.2.1.1. Isotonic Solution
    • 5.2.1.2. Antibiotic
    • 5.2.1.3. Others
    • 5.2.2. Dialysis
  • 5.3. Diagnosis
    • 5.3.1. Urine Test
    • 5.3.2. Blood Test
    • 5.3.3. Glomerular Filtration Rate (GFR)
    • 5.3.4. Imaging Test
    • 5.3.5. Kidney Biopsy

6. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY TYPE OF RRT

  • 6.1. Introduction
  • 6.2. Continuous
  • 6.3. Intermittent

7. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Component
    • 7.2.2. By Type of RRT
    • 7.2.3. By Country
    • 7.2.3.1. USA
    • 7.2.3.2. Canada
    • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Component
    • 7.3.2. By Type of RRT
    • 7.3.3. By Country
    • 7.3.3.1. Brazil
    • 7.3.3.2. Argentina
    • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Component
    • 7.4.2. By Type of RRT
    • 7.4.3. By Country
    • 7.4.3.1. Germany
    • 7.4.3.2. France
    • 7.4.3.3. United Kingdom
    • 7.4.3.4. Spain
    • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Component
    • 7.5.2. By Type of RRT
    • 7.5.3. By Country
    • 7.5.3.1. Saudi Arabia
    • 7.5.3.2. UAE
    • 7.5.3.3. Israel
    • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Component
    • 7.6.2. By Type of RRT
    • 7.6.3. By Country
    • 7.6.3.1. China
    • 7.6.3.2. Japan
    • 7.6.3.3. South Korea
    • 7.6.3.4. India
    • 7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Exponential Biotherapies, Inc.
  • 9.2. Nikkiso America, Inc.
  • 9.3. Am-Pharma
  • 9.4. Renalguard Solutions, Inc.
  • 9.5. Angion Biomedica Corp.
  • 9.6. Thrasos Therapeutics Inc.
  • 9.7. Atoxbio
  • 9.8. Sentien Biotechnologies, Inc